Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine
Open Access
- 1 May 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (5) , 1586-1588
- https://doi.org/10.1128/aac.46.5.1586-1588.2002
Abstract
Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.Keywords
This publication has 15 references indexed in Scilit:
- Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot studyThe Lancet, 2001
- Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutantsHepatology, 2000
- Antiretroviral Drug Resistance Testing in Adult HIV-1 InfectionJAMA, 2000
- Adefovir for the Treatment of HIV InfectionPublished by American Medical Association (AMA) ,1999
- Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral TherapyA Randomized Controlled TrialJAMA, 1999
- Mutations in Hepatitis B Dna Polymerase Associated With Resistance to Lamivudine Do Not Confer Resistance to Adefovir In VitroHepatology, 1998
- Comparison of liver progenitor cells in human atypical ductular reactions with those seen in experimental models of liver injuryHepatology, 1998
- Anti‐Human Immunodeficiency Virus (HIV) Activity, Safety, and Pharmacokinetics of Adefovir Dipivoxil (9‐[2‐(bis‐pivaloyloxymethyl)‐phosphonylmethoxyethyl]adenine) in HIV‐Infected PatientsThe Journal of Infectious Diseases, 1997
- K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenineAntimicrobial Agents and Chemotherapy, 1995
- Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agentsAntimicrobial Agents and Chemotherapy, 1988